|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||10.43 - 10.43|
|52-week range||10.43 - 10.43|
|Beta (5Y monthly)||2.04|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
Ladies and gentlemen, thank you for standing by, and welcome to Sangamo Therapeutics Inc Q3 2020 webcast. With me this afternoon on this call are several members of the same demo executive leadership team, including Sandy Macrae, Chief Executive Officer.
Sangamo (SGMO) delivered earnings and revenue surprises of 95.83% and 101.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?